Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.
Journal: Circulation. Cardiovascular quality and outcomes
Published: June 03, 2024
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48.
Journal: Journal of the American College of Cardiology
Published: April 07, 2021
Stroke prevention in atrial fibrillation: Closing the gap.
Journal: American heart journal
Published: October 10, 2018
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Journal: European heart journal
Published: May 05, 2018
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.
Journal: International journal of cardiology
Published: August 24, 2017
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.
Journal: Journal of the American Heart Association
Published: July 02, 2017
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
Journal: Journal of the American Heart Association
Published: July 13, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Journal: American heart journal
Published: August 26, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
Journal: European heart journal
Published: August 26, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026